The DFS and overall survival by treatment arm for favorable, intermediate, and unfavorable cytogenetic risk groups. Results are shown according to the CALGB classification for cumulative incidence of relapse.11 There were only small numbers of patients within several subsets, and the 95% CIs at 5 years (vertical bars) overlap for each comparison. (A) DFS by treatment regimen among patients with favorable risk cytogenetics. (B) Survival by treatment regimen among patients with favorable risk cytogenetics. (C) DFS by treatment regimen among patients with intermediate risk cytogenetics. (D) Survival by treatment regimen among patients with intermediate risk cytogenetics. (E) DFS by treatment regimen among patients with unfavorable risk cytogenetics. (F) Survival by treatment regimen among patients with unfavorable risk cytogenetics.
